Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates in two segments: Generics and Specialty. It manufactures and sells a portfolio of injectable products across various therapeutic areas. The Company markets its products to wholesalers, distributors, retail pharmacy chains, group purchasing organizations, government entities, independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers.

Type
Public
HQ
Canonsburg, US
Founded
1961
Size (employees)
35,000 (est)
Website
mylan.com
Mylan was founded in 1961 and is headquartered in Canonsburg, US
Report incorrect company information

Key People/Management at Mylan

Heather Bresch

Heather Bresch

Chief Executive Officer
Robert Coury

Robert Coury

Non-Executive Director
Wendy Cameron

Wendy Cameron

Non-Executive Director
Robert Cindrich

Robert Cindrich

Non-Executive Director
JoEllen Lyons Dillon

JoEllen Lyons Dillon

Executive Vice-President, Chief Legal Officer

Mylan Office Locations

Mylan has offices in Hertfordshire and Canonsburg
Canonsburg, US (HQ)
1000 Mylan Boulevard
Hertfordshire, GB
Building 4 Trident Place Mosquito Way
Show all (2)
Report incorrect company information

Mylan Financials and Metrics

Mylan Financials

Mylan's revenue was reported to be $7.65 b in FY, 2014 which is a 11.5% increase from the previous period.
USD

Revenue (FY, 2014)

7.6 b

Revenue growth (FY, 2013 - FY, 2014), %

11.5%

Gross profit (FY, 2014)

3.5 b

Gross profit margin (FY, 2014), %

45.2%

Net income (FY, 2014)

933.1 m

Market capitalization (23-Apr-2018)

21.9 b

Cash (31-May-2017)

24.2 k
Mylan's current market capitalization is $21.9 b.
USDFY, 2013FY, 2014

Revenue

6.9 b7.6 b

Revenue growth, %

12%

Cost of goods sold

3.9 b4.2 b

Gross profit

3 b3.5 b
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.5 k5.9 k1.8 k163 32 5.1 k5.2 k28.9 k15.3 k28.7 k24.2 k

Accounts Receivable

975 372 2.5 k17.4 k5.4 k5 k9.3 k20 k12.7 k54.9 k

Inventories

1.7 b1.7 b

Current Assets

3.4 k5.9 k2.2 k2.6 k17.4 k10.5 k10.2 k38.1 k35.3 k41.4 k79.1 k
USDFY, 2013FY, 2014

Net Income

626.5 m933.1 m

Depreciation and Amortization

516 m566.6 m

Inventories

(160 m)(150 m)

Accounts Payable

137.2 m(300 k)
USDY, 2017

Financial Leverage

416.8 x
Show all financial metrics
Report incorrect company information

Mylan News and Updates

Squeezed Mylan axing 500 jobs in West Virginia to 'right-size' massive plant

With a generics pricing squeeze hitting the entire copycat drug industry, Mylan is laying off about 500 employees in Morgantown, West Virginia. The cuts will simplify the site—among pharma's largest—which is now too complex, the company said.

Mylan cuts 15 pct of workforce at West Virginia plant

April 20 (Reuters) - Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia.

Mylan in advanced talks for Merck KGaA's $4B-plus OTC unit: report

Pfizer may have run into snags trying to sell its consumer health business, but Merck KGaA is in advanced discussions with a player over its own for-sale unit. And that player is Mylan, reports reveal.

Mylan seeks deal for German Merck’s consumer products unit: sources

FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.

Mylan seeks deal for German Merck’s consumer products unit -sources

FRANKFURT/NEW YORK, April 13 (Reuters) - Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter said.
Show more
Report incorrect company information